- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NATTOPHARMA Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 40,640 | +5,26 % | Genentech, Ionis Reveal Positive Interim Data From Phase III Sefaxersen Study In IgA Nephropathy | SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW), and partner Ionis Pharmaceuticals, Inc. (IONS) announced Wednesday positive... ► Artikel lesen | |
| CSPC PHARMA | 1,016 | -3,90 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - DATA FROM PHASE I CLINICAL STUDY OF SYS6002 AS MONOTHERAPY FOR THE TREATMENT OF ADVANCED CERVICAL CANCER ... | ||
| SELLAS LIFE SCIENCES | 10,400 | +3,48 % | SELLAS Life Sciences Group Inc mit PAUKENSCHLAG: Folgt jetzt der nächste Kursrutsch? - Unbedingt noch vor Börsenschluss lesen! | ||
| MADRIGAL PHARMACEUTICALS | 425,00 | -0,02 % | Madrigal: Rezdiffra zeigt in MASH-Studie konsistente Wirksamkeit über genetische Varianten hinweg | ||
| ACADIA PHARMACEUTICALS | 17,620 | +0,92 % | RBC Capital bestätigt Einstufung für Acadia Pharmaceuticals nach Patent-Entwicklungen | ||
| CATALYST PHARMACEUTICALS | 27,300 | +2,63 % | Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals | The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare DiseasesCompletion of the transaction gives Angelini Pharma ownership... ► Artikel lesen | |
| OPUS GENETICS | 4,200 | +5,53 % | Could an FDA Nod for MR-141 Give Viatris (VTRS) and Opus Genetics (IRD) a Presbyopia Payoff? | ||
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2027 Ended June 30, 2026 and Provides Conference Call Information | Northvale, New Jersey--(Newsfile Corp. - August 13, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 4,439 | +2,95 % | Citizens reiterates Savara stock rating on Molbreevi launch outlook | ||
| GALECTIN THERAPEUTICS | 3,200 | +0,63 % | Galectin Therapeutics Inc.: Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 | ||
| BIODEXA PHARMACEUTICALS | 0,461 | -11,97 % | Biodexa Pharmaceuticals Plc - 6-K, Report of foreign issuer | ||
| CGN MINING | 0,228 | 0,00 % | CGN MINING (01164): INTERIM REPORT 2026 | ||
| PHOTOCURE | 4,415 | -1,78 % | Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II | OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed... ► Artikel lesen | |
| ARCTICZYMES TECHNOLOGIES | 1,840 | +0,27 % | ArcticZymes Technologies ASA to present at the Swiss Nordic Bio 2026 Conference | ||
| NEURIZON THERAPEUTICS | 0,048 | 0,00 % | NEURIZON THERAPEUTICS LIMITED: Updated Investor Presentation and Webinar Reminder |
NATTOPHARMA ASA gehört der Branche Pharma an.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NATTOPHARMA ASA finden Sie auf Wallstreet Online.